

References

I-270

1. Epcoritamab (epcoritamab-bysp) injection, for subcutaneous use [package insert]. Genmab US, Inc. Plainsboro, NJ. Revised 05/2023.
2. Clinical PharmacologyTM Compendium. 2023. Tampa FL: Gold Standard, Inc. Epcoritamab.
3. Micromedex DrugDex Compendium®. 2023. Epcoritamab-bysp.
4. National Comprehensive Cancer Network (NCCN). Epcoritamab-bysp. NCCN Drugs and Biologics Compendium®. 2023.
5. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023;41(12):2238-2247.